{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T08:56:13Z","timestamp":1777280173054,"version":"3.51.4"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T00:00:00Z","timestamp":1639180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81771364"],"award-info":[{"award-number":["81771364"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81801203"],"award-info":[{"award-number":["81801203"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"publisher","award":["2018JJ2644"],"award-info":[{"award-number":["2018JJ2644"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"publisher","award":["2019JJ50973"],"award-info":[{"award-number":["2019JJ50973"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010451","name":"Health and Family Planning Commission of Hunan Province","doi-asserted-by":"publisher","award":["B2019181"],"award-info":[{"award-number":["B2019181"]}],"id":[{"id":"10.13039\/501100010451","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014978","name":"Hunan University of Chinese Medicine","doi-asserted-by":"publisher","award":["2019YSZJJ 12"],"award-info":[{"award-number":["2019YSZJJ 12"]}],"id":[{"id":"10.13039\/501100014978","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.msard.2021.103446","type":"journal-article","created":{"date-parts":[[2021,12,12]],"date-time":"2021-12-12T17:24:50Z","timestamp":1639329890000},"page":"103446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Serological markers exploration and real-world effectiveness and safety of teriflunomide in south Chinese patients with multiple sclerosis"],"prefix":"10.1016","volume":"58","author":[{"given":"Ran","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongliang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haobing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangjuan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuming","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2021.103446_bib0001","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40265-014-0212-x","article-title":"Teriflunomide and its mechanism of action in multiple sclerosis","volume":"74","author":"Bar-Or","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.msard.2021.103446_bib0002","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1093\/brain\/awy154","article-title":"Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis","volume":"141","author":"Barro","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.msard.2021.103446_bib0003","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jamaneurol.2019.3238","article-title":"Serum neurofilament light chain levels in patients with presymptomatic multiple sclerosis","volume":"77","author":"Bjornevik","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2021.103446_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2016.04.015","article-title":"T cell cytokine signatures: biomarkers in pediatric multiple sclerosis","volume":"297","author":"Cala","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2021.103446_bib0005","doi-asserted-by":"crossref","unstructured":"Cant\u00f3, E., Barro, C., Zhao, C., Caillier, S.J., Michalak, Z., Bove, R., Tomic, D., Santaniello, A., H\u00e4ring, D.A., Hollenbach, J., Henry, R.G., Cree, B.A.C., Kappos, L., Leppert, D., Hauser, S.L., Benkert, P., Oksenberg, J.R., Kuhle, J., 2019. Association between serum neurofilament light chain levels and long-term disease course among patients with multiple sclerosis followed up for 12 Years 1\u20138. 10.1001\/jamaneurol.2019.2137.","DOI":"10.1001\/jamaneurol.2019.2137"},{"key":"10.1016\/j.msard.2021.103446_bib0006","article-title":"Stimulation of proliferation and migration of mouse macrophages by type B CpG-ODNs is F-spondin and IL-1Ra dependent","volume":"10","author":"Chen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2021.103446_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2018.02.015","article-title":"The roles of macrophages and microglia in multiple sclerosis and experimental autoimmune encephalomyelitis","volume":"318","author":"Chu","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2021.103446_bib0008","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.msard.2015.11.006","article-title":"Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions","volume":"5","author":"Comi","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103446_bib0009","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/ene.13839","article-title":"Dimethyl fumarate and teriflunomide for multiple sclerosis in a real-life setting: a French retrospective cohort study","volume":"26","author":"Cond\u00e9","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2021.103446_bib0010","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","article-title":"Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Confavreux","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2021.103446_bib0011","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.msard.2017.07.006","article-title":"Patient-reported outcomes in relapsing forms of MS: real-world, global treatment experience with teriflunomide from the Teri-PRO study","volume":"17","author":"Coyle","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103446_bib0012","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1158\/1078-0432.CCR-04-0144","article-title":"ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition","volume":"10","author":"de Jong","year":"2004","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.msard.2021.103446_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102659","article-title":"Fatigue in teriflunomide-treated patients with relapsing remitting multiple sclerosis in the real-world Teri-FAST study","volume":"47","author":"de S\u00e8ze","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103446_bib0014","article-title":"Blood neurofilament light levels segregate treatment effects in multiple sclerosis","volume":"0","author":"Delcoigne","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103446_bib0015","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418791103","article-title":"Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod","volume":"11","author":"Diem","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2021.103446_bib0016","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum Neurofilament light: a biomarker of neuronal damage in multiple sclerosis","volume":"81","author":"Disanto","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2021.103446_bib0017","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1212\/WNL.0000000000002832","article-title":"Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab","volume":"87","author":"Flon","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103446_bib0018","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1002\/eji.201142227","article-title":"IL-13-producing Th1 and Th17 cells characterize adaptive responses to both self and foreign antigens","volume":"42","author":"Gallo","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.msard.2021.103446_bib0019","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3389\/fimmu.2020.00594","article-title":"Expansion of neutrophils and classical and nonclassical monocytes as a hallmark in relapsing-remitting multiple sclerosis","volume":"11","author":"Haschka","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2021.103446_bib0020","article-title":"Teriflunomide for multiple sclerosis","volume":"3","author":"He","year":"2016","journal-title":"Cochrane database Syst. Rev."},{"key":"10.1016\/j.msard.2021.103446_bib0021","doi-asserted-by":"crossref","first-page":"12952","DOI":"10.1073\/pnas.1912839117","article-title":"Inflammation-related plasma and CSF biomarkers for multiple sclerosis","volume":"117","author":"Huang","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.msard.2021.103446_bib0022","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211005588","article-title":"Teriflunomide in relapsing-remitting multiple sclerosis: outcomes by age and pre-treatment status","volume":"14","author":"Kallmann","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2021.103446_bib0023","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419835077","article-title":"Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study","volume":"12","author":"Kallmann","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2021.103446_bib0024","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00228-010-0916-0","article-title":"Effect of ABCG2 genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric acid level","volume":"67","author":"Kim","year":"2011","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.msard.2021.103446_bib0025","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1212\/WNL.0000000000001491","article-title":"Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis","volume":"84","author":"Kuhle","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103446_bib0026","doi-asserted-by":"crossref","first-page":"E1007","DOI":"10.1212\/WNL.0000000000007032","article-title":"Blood neurofilament light chain as a biomarker of MS disease activity and treatment response","volume":"92","author":"Kuhle","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103446_bib0027","doi-asserted-by":"crossref","DOI":"10.3390\/cells9020482","article-title":"T helper cells: the modulators of inflammation in multiple sclerosis","volume":"9","author":"Kunkl","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.msard.2021.103446_bib0028","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: results of an international survey. National multiple sclerosis society (USA) advisory committee on clinical trials of new agents in multiple sclerosis","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103446_bib0029","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1136\/annrheumdis-2017-212652","article-title":"Expansion of T follicular helper-T helper 1 like cells through epigenetic regulation by signal transducer and activator of transcription factors","volume":"77","author":"Ma","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.msard.2021.103446_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.101935","article-title":"No evidence of disease activity\u201d: is it an aspirational therapeutic goal in multiple sclerosis?","volume":"40","author":"Mayssam","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103446_bib0031","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1177\/1352458509355068","article-title":"Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid","volume":"16","author":"Mellerg\u00e5rd","year":"2010","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103446_bib0032","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1177\/1352458512450354","article-title":"Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis","volume":"18","author":"Miller","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103446_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102438","article-title":"Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: results from the TOWER extension study","volume":"46","author":"Miller","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103446_bib0034","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1474-4422(14)70191-7","article-title":"Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Miller","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2021.103446_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102647","article-title":"The role of TH17 cells in multiple sclerosis: therapeutic implications","volume":"19","author":"Moser","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.msard.2021.103446_bib0036","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1177\/1352458516639384","article-title":"Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis","volume":"23","author":"Novakova","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103446_bib0037","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1084\/jem.20090246","article-title":"IL-9 as a mediator of Th17-driven inflammatory disease","volume":"206","author":"Nowak","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.msard.2021.103446_bib0038","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O'Connor","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.103446_bib0039","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1177\/1352458517715132","article-title":"Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod","volume":"24","author":"Piehl","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103446_bib0040","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1007\/s00415-018-9070-x","article-title":"No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study","volume":"265","author":"Prosperini","year":"2018","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2021.103446_bib0041","first-page":"2776","article-title":"Efficacy and safety of teriflunomide in Chinese patients with relapsing forms of multiple sclerosis: a subgroup analysis of the phase 3 TOWER study","volume":"131","author":"Qiu","year":"2018","journal-title":"Chin. Med. J. Engl."},{"key":"10.1016\/j.msard.2021.103446_bib0042","doi-asserted-by":"crossref","DOI":"10.1038\/d41586-018-07063-z","article-title":"Immune-cell crosstalk in multiple sclerosis","author":"Ransohoff","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.msard.2021.103446_bib0043","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1212\/WNL.0000000000000361","article-title":"Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial","volume":"82","author":"Romme Christensen","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103446_bib0044","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1084\/jem.20141015","article-title":"Neutrophil-related factors as biomarkers in EAE and MS","volume":"212","author":"Rumble","year":"2015","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.msard.2021.103446_bib0045","first-page":"1324","article-title":"Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment na\u00efve relapsing MS patients","volume":"90","author":"Sejbaek","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.msard.2021.103446_bib0046","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12974-018-1150-4","article-title":"Platelet-derived growth factor predicts prolonged relapse-free period in multiple sclerosis","volume":"15","author":"Stampanoni Bassi","year":"2018","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.msard.2021.103446_bib0047","series-title":"Atlas of MS 3rd Edition","first-page":"1","year":"2020"},{"key":"10.1016\/j.msard.2021.103446_bib0048","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2021.103446_bib0049","doi-asserted-by":"crossref","DOI":"10.3390\/cells8030285","article-title":"IL-6, IL-12, and IL-23 STAT-pathway genetic risk and responsiveness of lymphocytes in patients with multiple sclerosis","volume":"8","author":"von Essen","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.msard.2021.103446_bib0050","doi-asserted-by":"crossref","first-page":"i3518","DOI":"10.1136\/bmj.i3518","article-title":"Disease modifying therapies for relapsing multiple sclerosis","volume":"354","author":"Wingerchuk","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.msard.2021.103446_bib0051","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/cvr\/cvr148","article-title":"IL-6-mediated Th17 differentiation through ROR\u03b3t is essential for the initiation of experimental autoimmune myocarditis","volume":"91","author":"Yamashita","year":"2011","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.msard.2021.103446_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102875","article-title":"No evidence of disease activity-3 (NEDA-3) status in patients with relapsing remitting multiple sclerosis: evidence from Saudi cohort receiving mainly interferon","volume":"51","author":"Zafar","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103446_bib0053","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3389\/fneur.2021.651511","article-title":"Status of immunotherapy acceptance in Chinese patients with multiple sclerosis: analysis of multiple sclerosis patient survival report 2018","volume":"12","author":"Zhou","year":"2021","journal-title":"Front. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821007124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821007124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:58:06Z","timestamp":1761901086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821007124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":53,"alternative-id":["S2211034821007124"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.103446","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serological markers exploration and real-world effectiveness and safety of teriflunomide in south Chinese patients with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.103446","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103446"}}